Results 101 to 110 of about 29,282 (210)

Update on fosfomycin-modified genes in Enterobacteriaceae

open access: yesJournal of Microbiology, Immunology and Infection, 2019
The long-used antibiotic fosfomycin has recently been re-evaluated as a potential regimen for treating extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE).
Tsung-Ying Yang   +2 more
doaj   +1 more source

An Efficient, One-Pot Synthesis of Fosfomycin Dialkyl Esters from (R)-2-Tosyloxypropanal [PDF]

open access: yes, 2007
(R)-2-Tosyloxypropanal (4) was prepared from D-mannitol in a 7-step sequence (51% overall yield). Addition of dialkyl phosphonates to 4 in the presence of titanium isopropoxide and the subsequent treatment with DBU stereoselectively afforded, in one-pot,
Hanaya, Tadashi   +2 more
core   +1 more source

Vm–MSI: a Vancomycin–Antimicrobial Peptide Conjugate Combating Resistant Bacteria and Broadening the Antimicrobial Spectrum

open access: yesAdvanced Science, Volume 13, Issue 11, 23 February 2026.
A series of vancomycin‐antimicrobial peptide conjugates is synthesized and evaluated to identify the optimal combination. Vm‐MSI, selected from multiple candidates, exhibited potent activity against vancomycin‐resistant and Gram‐negative bacteria by disrupting membranes and inducing oxidative stress, thereby expanding vancomycin's antibacterial ...
Shuangyu Li   +7 more
wiley   +1 more source

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 2016
Fosfomycin is a new agent to Canada approved for the treatment of acute uncomplicated cystitis (AUC) in adult women infected with susceptible isolates of E. coli and Enterococcus faecalis.
George G. Zhanel   +2 more
doaj   +1 more source

Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital

open access: yesSouthern African Journal of Infectious Diseases, 2020
Background: Multidrug-resistant uropathogens are becoming widespread both in community and hospital setting. Safe yet effective treatments are a priority.
Lesego M. Mothibi   +2 more
doaj   +1 more source

Exploring dangerous connections between Klebsiella pneumoniae biofilms and healthcare-associated infections [PDF]

open access: yes, 2014
Healthcare-associated infections (HAI) are a huge public health concern,particularly when the etiological agents are multidrug resistant. The ability of bacteria to develop biofilm is a helpful skill, both to persist within hospital units and to ...
Bandeira, Maria   +3 more
core   +2 more sources

Lemierre's Syndrome Caused by Klebsiella pneumoniae: Case Report and Review of the Literature

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
Axial contrast‐enhanced chest CT demonstrating multiple peripheral cavitary nodules and consolidations, predominantly in the right lower lobe, consistent with septic pulmonary emboli (arrows). ABSTRACT Klebsiella pneumoniae is an uncommon but increasingly recognized cause of Lemierre's syndrome, a condition classically associated with Fusobacterium ...
Abril Aguilar Guerrero   +1 more
wiley   +1 more source

In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae

open access: yesJournal of Global Antimicrobial Resistance, 2020
Objectives: The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by ...
Ausilia Aprile   +3 more
doaj   +1 more source

Introducing TeHyperBTM as an Organocatalyst for (4 + 2)‐Cycloadditions of Michael Acceptors with Allenoates, But‐2‐ynoates or Allenylphosphonates

open access: yesChemistryEurope, Volume 4, Issue 2, February 2026.
TeHyperBTM is introduced as a highly nucleophilic chiral Lewis basic organocatalyst that allows for asymmetric (4 + 2)‐cycloadditions of allenoates and Michael acceptors, where its analogous S‐ and Se‐variants come to their limits. TeHyperBTM [= (2S,3R)‐3‐isopropyl‐2‐phenyl‐3,4‐dihydro‐2H‐benzo[4,5][1,3]tellurazolo[3,2‐a]pyrimidine] is introduced as a ...
Magdalena Piringer   +6 more
wiley   +1 more source

Efficacy of high doses of intravenous fosfomycin for treatment of urinary tract infection caused by KPC carbapenemase-producing Klebsiella pneumoniae: An observational study

open access: yesJournal of Global Antimicrobial Resistance
: Objective: To evaluate the efficacy of high-dose intravenous fosfomycin for the treatment of urinary tract infections (UTI) caused by KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp).
Jorge Rodríguez-Gómez   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy